Publication | Open Access
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
809
Citations
14
References
1995
Year
In a preliminary trial, 12 weeks of lamivudine therapy was well tolerated, and daily doses of 100 mg and 300 mg reduced HBV DNA to undetectable levels.
| Year | Citations | |
|---|---|---|
Page 1
Page 1